Protagonist Therapeutics (PTGX) Net Cash Flow (2015 - 2026)

Protagonist Therapeutics has reported Net Cash Flow for 12 years, with the latest figure at $65.3 million in Q1 2026.

• Quarterly Net Cash Flow rose 54.05% year-over-year to $65.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.1 million (up 264.43% YoY) and the FY2025 annual result came in at $31.2 million, up 134.87% from the prior year.
• Net Cash Flow improved to $65.3 million in Q1 2026 per PTGX's latest filing, from $14.7 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $183.1 million in Q2 2024 and troughed at -$224.5 million in Q3 2024.
• A 5-year average of $4.1 million and a median of $1.9 million in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow plunged 4524.55% in 2024, then soared 399.48% in 2025.
• Over 5 years, Net Cash Flow stood at -$27.1 million in 2022, then slumped by 61.34% to -$43.8 million in 2023, then advanced by 22.67% to -$33.9 million in 2024, then soared by 143.33% to $14.7 million in 2025, then surged by 345.07% to $65.3 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $65.3 million, $14.7 million, and -$54.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.